<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00079027</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000353298</org_study_id>
    <secondary_id>CRUK-HEP-1</secondary_id>
    <secondary_id>EU-20340</secondary_id>
    <secondary_id>ISRCTN78345798</secondary_id>
    <nct_id>NCT00079027</nct_id>
  </id_info>
  <brief_title>Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)</brief_title>
  <official_title>A Randomized Clinical Trial Evaluating the Benefits of Doxorubicin Chemoembolization Versus Systemic Doxorubicin in Patients With Unresectable, Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells or by stopping the cells from&#xD;
      dividing. Chemoembolization kills tumor cells by blocking the blood flow to the tumor and&#xD;
      keeping chemotherapy drugs near the tumor. It is not yet known whether doxorubicin is more&#xD;
      effective with or without chemoembolization in treating unresectable hepatocellular carcinoma&#xD;
      (liver cancer).&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying doxorubicin given by infusion to see how&#xD;
      well it works compared to doxorubicin given by chemoembolization in treating patients with&#xD;
      advanced liver cancer than cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the survival of patients with advanced unresectable primary hepatocellular&#xD;
           carcinoma treated with intravenous doxorubicin hydrochloride vs doxorubicin&#xD;
           hydrochloride chemoembolization.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the response rate in patients treated with these regimens.&#xD;
&#xD;
        -  Compare time to progression in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the toxicity of these regimens in these patients.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the health economic implications of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, controlled, multicenter study. Patients are stratified&#xD;
      according to participating center, stage of disease, and alpha-fetoprotein levels (&lt; 500&#xD;
      ng/mL vs ≥ 500 ng/mL). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I (control arm): Patients receive doxorubicin hydrochloride IV over 3-5 minutes on&#xD;
           day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II (chemoembolization arm): Patients undergo transarterial chemoembolization using&#xD;
           DC Bead and doxorubicin hydrochloride. Chemoembolization repeats every 8 weeks for a&#xD;
           total of 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline and at weeks 10 and 24.&#xD;
&#xD;
      Patients are followed at 4 weeks and then every 12 weeks thereafter.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 280 patients (140 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2004</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed by EORTC QOL QLQ-30 and EORTC QLQ HCC18 at baseline and 10 and 24 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression as assessed by RECIST criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteomic and immunological analysis</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Liver Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hepatic artery embolization</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed hepatocellular carcinoma (HCC)&#xD;
&#xD;
               -  Advanced, unresectable disease&#xD;
&#xD;
          -  No clinically significant ascites&#xD;
&#xD;
          -  No modified Child-Pugh class C liver disease&#xD;
&#xD;
          -  No main portal vein occlusion/involvement&#xD;
&#xD;
          -  No extrahepatic tumor of any kind&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over (16 and over for patients residing in Scotland)&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8.5 g/dL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 5.0 mg/dL&#xD;
&#xD;
          -  Transaminases &lt; 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  INR &lt; 1.5&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 2 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III or IV cardiac disease&#xD;
&#xD;
          -  No acute angina&#xD;
&#xD;
          -  No significant peripheral vascular disease&#xD;
&#xD;
          -  No thrombosis of main portal vein&#xD;
&#xD;
          -  LVEF ≥ 50%&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other concurrent serious medical condition&#xD;
&#xD;
          -  No serious infection&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical factors that would preclude&#xD;
             study compliance&#xD;
&#xD;
          -  No other malignancy within the past 5 years except carcinoma in situ of the cervix or&#xD;
             non-melanoma skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior biologic therapy for advanced unresectable HCC&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior systemic or regional chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for advanced unresectable HCC&#xD;
&#xD;
          -  No other concurrent anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No prior hormonal therapy for advanced unresectable HCC&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy for advanced unresectable HCC&#xD;
&#xD;
          -  No other concurrent anticancer radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 7 days since prior major surgery&#xD;
&#xD;
          -  More than 3 days since prior laparoscopy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior investigational agents&#xD;
&#xD;
          -  More than 6 weeks since prior ablative therapy and must have radiological evidence of&#xD;
             progression if ablated site is the only site of disease&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>O. J. Garden</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Infirmary of Edinburgh at Little France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Research UK Clinical Trials Unit - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L69 3GA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W12 OHS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal South Hants Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO14 0YG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh at Little France</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH3 9YW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>March 8, 2004</study_first_submitted>
  <study_first_submitted_qc>March 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2004</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

